Heart transplantation indications: Difference between revisions

Jump to navigation Jump to search
 
(11 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Heart transplantation}}
{{Heart transplantation}}


'''Editor(s)-in-Chief:''' [[C. Michael  Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}
'''Editor(s)-in-Chief:''' [[C. Michael  Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}{{IF}}
 
==Overview==
Patients requiring a cardiac transplant are generally with advanced, irreversible heart failure with a severely limited life expectancy. These patients would have failed medical and device therapy. Common indications include causes that led to this like- [[systolic heart failure]] with a left ventricular [[ejection fraction]] less than 35%, [[Ischemia|ischemic]] [[coronary artery disease]] with [[Angina|refractory angina]], intractable life-threatening [[Cardiac arrhythmia|arrhythmias]], [[Cardiomyopathy|cardiomyopathies]], and [[Congenital heart disease|congenital heart disease.]]


==Indications==  
==Indications==  
In order for a patient to be recommended for a heart transplant they will generally have advanced, irreversible [[heart failure]] with a severely limited [[life expectancy]].<ref name="pmid11397947">{{cite journal |author=Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH |title=Guidelines for the referral and management of patients eligible for solid organ transplantation |journal=[[Transplantation]] |volume=71 |issue=9 |pages=1189–204 |year=2001 |month=May |pmid=11397947 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0041-1337&volume=71&issue=9&spage=1189 |issn=}}</ref> It is important to note that the life expectancy of [[heart failure]] has improved over the past two decades due to improvements in both medical therapy ([[ACE Inhibition]], [[beta-blockers]], [[aldosterone antagonists]] and device therapy such as [[automatic implantable cardiac defibrillator]]s [[AICD]]s and [[cardiac resynchronization]]. Thus, patients should not be considered for cardiac transplantation unless they have failed aggressive medical and device therapy.
In order for a patient to be recommended for a heart transplant they will generally have advanced, irreversible [[heart failure]] with a severely limited [[life expectancy]].<ref name="pmid11397947">{{cite journal |author=Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH |title=Guidelines for the referral and management of patients eligible for solid organ transplantation |journal=[[Transplantation]] |volume=71 |issue=9 |pages=1189–204 |year=2001 |month=May |pmid=11397947 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0041-1337&volume=71&issue=9&spage=1189 |issn=}}</ref> It is important to note that the life expectancy of [[heart failure]] has improved over the past two decades due to improvements in both medical therapy ([[ACE Inhibition]], [[beta-blockers]], [[aldosterone antagonists]] and device therapy such as [[automatic implantable cardiac defibrillator]]s [[AICD]]s and [[cardiac resynchronization]]. Thus, patients should not be considered for cardiac transplantation unless they have failed aggressive medical and device therapy. <ref name="pmid25132979">{{cite journal| author=Alraies MC, Eckman P| title=Adult heart transplant: indications and outcomes. | journal=J Thorac Dis | year= 2014 | volume= 6 | issue= 8 | pages= 1120-8 | pmid=25132979 | doi=10.3978/j.issn.2072-1439.2014.06.44 | pmc=4133547 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25132979  }} </ref><ref name="pmid17261651">{{cite journal| author=Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK | display-authors=etal| title=Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. | journal=Circulation | year= 2007 | volume= 115 | issue= 5 | pages= 658-76 | pmid=17261651 | doi=10.1161/CIRCULATIONAHA.106.180449 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17261651  }} </ref>
   
   
===Systolic Heart Failure with a Left Ventricular Ejection Fraction less than 35%===  
===Systolic Heart Failure with a Left Ventricular Ejection Fraction less than 35%<ref name="pmid26776864">{{cite journal| author=Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA | display-authors=etal| title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. | journal=J Heart Lung Transplant | year= 2016 | volume= 35 | issue= 1 | pages= 1-23 | pmid=26776864 | doi=10.1016/j.healun.2015.10.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26776864  }} </ref>===  


<ref name="pmid26776864">{{cite journal| author=Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA | display-authors=etal| title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. | journal=J Heart Lung Transplant | year= 2016 | volume= 35 | issue= 1 | pages= 1-23 | pmid=26776864 | doi=10.1016/j.healun.2015.10.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26776864  }} </ref>
Due to either:


*Due to either:
*Ischemic [[cardiomyopathy]]
:*Ischemic [[cardiomyopathy]]
*Dilated [[cardiomyopathy]]
:*Dilated [[cardiomyopathy]]
*[[Valvular heart disease]]
:*[[Valvular heart disease]]
*[[Hypertensive heart disease]]
:*[[Hypertensive heart disease]]
*''Etiologies which are excluded are [[amyloid]], [[HIV]], and cardiac [[sarcoma]]''
:*''Etiologies which are excluded are [[amyloid]], [[HIV]], and cardiac [[sarcoma]]''


===Ischemic Coronary Artery Disease with Refractory Angina===  
===Ischemic Coronary Artery Disease with Refractory Angina===  
*Ischemia which is not amenable to percutaneous or surgical revascularization ([[coronary artery bypass graft surgery]] CABG) and is refractory to maximally tolerated medical and/or device therapy
 
*Ischemia which is not amenable to percutaneous or surgical revascularization ([[coronary artery bypass graft surgery]] CABG) and is refractory to maximally tolerated medical and/or device therapy. <ref name="pmid27772668">{{cite journal| author=Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ | display-authors=etal| title=The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. | journal=J Heart Lung Transplant | year= 2016 | volume= 35 | issue= 10 | pages= 1158-1169 | pmid=27772668 | doi=10.1016/j.healun.2016.08.017 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27772668  }} </ref>


===Intractable life-threatening Arrhythmias===
===Intractable life-threatening Arrhythmias===
*[[Ventricular arrhythmias]] which are not controlled by an [[implantable cardioverter-defibrillator]] and are refractory or not amenable to electrophysiologic guided single or combination medical therapy
*[[Ventricular arrhythmias]] which are not controlled by an [[implantable cardioverter-defibrillator]] and are refractory or not amenable to electrophysiologic guided single or combination medical therapy
* Patients that are not a candidate for catheter ablation therapy
*Patients that are not a candidate for catheter ablation therapy. <ref name="pmid25132979">{{cite journal| author=Alraies MC, Eckman P| title=Adult heart transplant: indications and outcomes. | journal=J Thorac Dis | year= 2014 | volume= 6 | issue= 8 | pages= 1120-8 | pmid=25132979 | doi=10.3978/j.issn.2072-1439.2014.06.44 | pmc=4133547 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25132979  }} </ref>


===Cardiomyopathies===
===Cardiomyopathies===
*Restrictive and Hypertrophic Cardiomyopathies with [[New York heart association functional classification|NYHA Class IV]] [[heart failure]] symptoms that persist despite maximal medical therapy, [[myomectomy]], [[alcohol septal ablation]], [[mitral valve replacement]]
*Restrictive and Hypertrophic Cardiomyopathies with [[New York heart association functional classification|NYHA Class IV]] [[heart failure]] symptoms that persist despite maximal medical therapy, [[myomectomy]], [[alcohol septal ablation]], [[mitral valve replacement]]
*Non-dilated cardiomyopathies such as arrhythmogenic right ventricular cardiomyopathy
*Non-dilated cardiomyopathies such as arrhythmogenic right ventricular cardiomyopathy. <ref name="pmid25132979">{{cite journal| author=Alraies MC, Eckman P| title=Adult heart transplant: indications and outcomes. | journal=J Thorac Dis | year= 2014 | volume= 6 | issue= 8 | pages= 1120-8 | pmid=25132979 | doi=10.3978/j.issn.2072-1439.2014.06.44 | pmc=4133547 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25132979  }} </ref>


===Congenital Heart Disease===
===Congenital Heart Disease===
* CHD resulting in New York Heart Association functional class IV Heart Failure not amenable to surgery.
* Severe symptomatic cyanotic congenital heart disease.
* Presence of some degree of pulmonary hypertension with the potential risk of developing fixed and irreversible elevation of pulmonary vascular resistance (PVR)
===General Considerations===
According to The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation, the following general considerations should be taken into account to finalise the listing of a patient with relevant indications for heart transplant <ref name="pmid26776864">{{cite journal| author=Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA | display-authors=etal| title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. | journal=J Heart Lung Transplant | year= 2016 | volume= 35 | issue= 1 | pages= 1-23 | pmid=26776864 | doi=10.1016/j.healun.2015.10.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26776864  }} </ref>


* Cardiopulmonary stress testing to guide transplant listing
*CHD resulting in [[New York Heart Association (NYHA) class|New York Heart Association]] functional class IV Heart Failure not amenable to surgery.
* Use of heart failure prognosis scores - An estimated 1-year survival as calculated by the '''Seattle Heart Failure Model (SHFM)''' of < 80% or a '''Heart Failure Survival Score (HFSS)''' in the high/medium risk range should be considered as reasonable cut points for listing
*Severe symptomatic [[Congenital heart disease cyanotic|cyanotic congenital heart disease.]]
* Role of diagnostic right heart catheterization- should be performed on all adult candidates in preparation for listing for cardiac transplantation and periodically until transplantation
*Presence of some degree of [[pulmonary hypertension]] with the potential risk of developing fixed and irreversible elevation of [[pulmonary vascular resistance]] (PVR) <ref name="pmid25132975">{{cite journal| author=Thrush PT, Hoffman TM| title=Pediatric heart transplantation-indications and outcomes in the current era. | journal=J Thorac Dis | year= 2014 | volume= 6 | issue= 8 | pages= 1080-96 | pmid=25132975 | doi=10.3978/j.issn.2072-1439.2014.06.16 | pmc=4133537 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25132975  }} </ref>
* Comorbidities and their implications for heart transplantation listing
** Age (< 70 years), obesity ((BMI) > 35 kg/m 2 is associated with a worse outcome), and cancer
** Diabetes- End-organ damage and persistent poor glycemic control (glycosylated hemoglobin [HbA 1c] > 7.5% or 58 mmol/mol) are contraindications
** Renal dysfunction- irreversible renal dysfunction ( eGFR < 30 ml/min/1.73 m 2) is a relative contraindication
** Peripheral vascular disease- Clinically severe symptomatic cerebrovascular disease may be considered a contraindication.
** Assessment of frailty
** Mechanical circulatory support for bridge to candidacy
* Tobacco use, substance abuse, and psychosocial evaluation in candidates
* Substance abuse
* Psychosocial evaluation
* Guidance for screening grids and serial pre-transplant evaluation
* Dynamic listing and new donor allocation algorithms
* Retransplantation- indicated for those patients who develop significant CAV with refractory cardiac allograft dysfunction, without evidence of ongoing rejection


==References==
==References==

Latest revision as of 23:39, 12 January 2021

Heart transplantation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Complications and Prognosis

Diagnosis

Indications

Evaluation

Contraindications

Criteria for Cardiac Transplantation

Equitable Distribution of Donor Hearts to those Awaiting Transplantation and the Process of Being Listed for a Transplant

Treatment

Medical Therapy

Surgery

Follow-Up

Electrocardiogram and Pacing After Cardiac Transplantation

Heart transplantation indications On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heart transplantation indications

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heart transplantation indications

CDC onHeart transplantation indications

Heart transplantation indications in the news

Blogs on Heart transplantation indications

Directions to Hospitals Treating Heart transplantation

Risk calculators and risk factors for Heart transplantation indications

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D.; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1]Ifrah Fatima, M.B.B.S[2]

Overview

Patients requiring a cardiac transplant are generally with advanced, irreversible heart failure with a severely limited life expectancy. These patients would have failed medical and device therapy. Common indications include causes that led to this like- systolic heart failure with a left ventricular ejection fraction less than 35%, ischemic coronary artery disease with refractory angina, intractable life-threatening arrhythmias, cardiomyopathies, and congenital heart disease.

Indications

In order for a patient to be recommended for a heart transplant they will generally have advanced, irreversible heart failure with a severely limited life expectancy.[1] It is important to note that the life expectancy of heart failure has improved over the past two decades due to improvements in both medical therapy (ACE Inhibition, beta-blockers, aldosterone antagonists and device therapy such as automatic implantable cardiac defibrillators AICDs and cardiac resynchronization. Thus, patients should not be considered for cardiac transplantation unless they have failed aggressive medical and device therapy. [2][3]

Systolic Heart Failure with a Left Ventricular Ejection Fraction less than 35%[4]

Due to either:

Ischemic Coronary Artery Disease with Refractory Angina

  • Ischemia which is not amenable to percutaneous or surgical revascularization (coronary artery bypass graft surgery CABG) and is refractory to maximally tolerated medical and/or device therapy. [5]

Intractable life-threatening Arrhythmias

Cardiomyopathies

Congenital Heart Disease

References

  1. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH (2001). "Guidelines for the referral and management of patients eligible for solid organ transplantation". Transplantation. 71 (9): 1189–204. PMID 11397947. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 2.2 Alraies MC, Eckman P (2014). "Adult heart transplant: indications and outcomes". J Thorac Dis. 6 (8): 1120–8. doi:10.3978/j.issn.2072-1439.2014.06.44. PMC 4133547. PMID 25132979.
  3. Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MR, Kirklin JK; et al. (2007). "Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 115 (5): 658–76. doi:10.1161/CIRCULATIONAHA.106.180449. PMID 17261651.
  4. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA; et al. (2016). "The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update". J Heart Lung Transplant. 35 (1): 1–23. doi:10.1016/j.healun.2015.10.023. PMID 26776864.
  5. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ; et al. (2016). "The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant". J Heart Lung Transplant. 35 (10): 1158–1169. doi:10.1016/j.healun.2016.08.017. PMID 27772668.
  6. Thrush PT, Hoffman TM (2014). "Pediatric heart transplantation-indications and outcomes in the current era". J Thorac Dis. 6 (8): 1080–96. doi:10.3978/j.issn.2072-1439.2014.06.16. PMC 4133537. PMID 25132975.


Template:WikiDoc Sources